Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company, announced on Tuesday that the United States Patent and Trademark Office has issued a new patent for CM-101, Chemomab's first-in-class monoclonal antibody that neutralises CCL24, a novel disease target at the confluence of fibrosis and inflammation.
The new patent includes the use of CM-101 and sequence-related CCL24 antibodies to treat hepatic (liver) diseases. Presently, CM-101 is in a Phase two trial for the treatment of primary sclerosing cholangitis (PSC).
CM-101 is a monoclonal antibody that neutralises the soluble protein CCL24, a cytokine family member that can trigger self-reinforcing inflammatory and fibrotic pathways implicated in various serious progressive diseases.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients